Breast cancer checks missing most women under 50 who are at risk, says study
SkimNews Take
Using family history as the primary screening heuristic implicitly assumes heredity drives most cases, yet the 95% miss rate reveals the criterion functions as a convenient proxy rather than a true risk indicator — the barrier is deployment, not discovery.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- NICE guidelines for breast cancer screening under-50s miss up to 95% of those at higher risk because the criteria rely solely on inherited genes rather than lifestyle factors, according to a study in the British Journal of Cancer.
- The Cambridge/ICR team used the Boadicea risk calculator—combining family history, lifestyle, reproductive history, and genetic information—and identified 8 times as many women under 50 who developed breast cancer compared to current NICE criteria.
- Under the Boadicea tool, 26.5% of women under 50 would be referred for further assessment, capturing 34.8% of those who develop breast cancer within a decade, versus just 1.4% referred and 4.4% captured under current NICE criteria.
- 73% of women under 50 who develop breast cancer within a decade have no family history of the disease—the key criterion NICE uses to flag extra assessment.
- Lead researcher Dr Juliet Usher-Smith said the NHS should review the criteria, while acknowledging that more referrals would add to workloads and could cause unnecessary anxiety and checks.
- NICE said it welcomed the findings and recognized the potential of multifactorial risk tools but maintained current evidence does not warrant a change to its breast cancer guidelines.
- The UK invites women for screening starting at age 50 every three years, while Sweden begins at 40, and Australia and Canada screen every two years; breast cancer is a leading cause of death in UK women under 50.
Why it matters: NICE's family-history-only criteria capture 4.4% of under-50 breast cancer cases, while a broader tool identifies 34.8%—yet NICE says current evidence doesn't justify a change. The gap leaves the 73% of under-50 patients without family history—like Natasha Finch, diagnosed at 23 with no risk factors—dependent on self-advocacy rather than systematic screening.
